ATE510846T1 - Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden - Google Patents

Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden

Info

Publication number
ATE510846T1
ATE510846T1 AT06803140T AT06803140T ATE510846T1 AT E510846 T1 ATE510846 T1 AT E510846T1 AT 06803140 T AT06803140 T AT 06803140T AT 06803140 T AT06803140 T AT 06803140T AT E510846 T1 ATE510846 T1 AT E510846T1
Authority
AT
Austria
Prior art keywords
formula
compound
production
cyclizing
macrocyclic peptides
Prior art date
Application number
AT06803140T
Other languages
English (en)
Inventor
Chutian Shu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE510846T1 publication Critical patent/ATE510846T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06803140T 2005-09-09 2006-09-08 Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden ATE510846T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71553405P 2005-09-09 2005-09-09
PCT/US2006/034921 WO2007030656A1 (en) 2005-09-09 2006-09-08 Ring-closing metathesis process for the preparation of macrocyclic peptides

Publications (1)

Publication Number Publication Date
ATE510846T1 true ATE510846T1 (de) 2011-06-15

Family

ID=37549189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06803140T ATE510846T1 (de) 2005-09-09 2006-09-08 Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden

Country Status (9)

Country Link
US (1) US7951773B2 (de)
EP (1) EP1934243B1 (de)
JP (1) JP5190364B2 (de)
AT (1) ATE510846T1 (de)
CA (1) CA2621360C (de)
DK (1) DK1934243T3 (de)
ES (1) ES2364426T3 (de)
PL (1) PL1934243T3 (de)
WO (1) WO2007030656A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
NZ574605A (en) 2006-07-13 2011-11-25 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2008106130A2 (en) 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
US8193346B2 (en) * 2007-12-06 2012-06-05 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis C protease inhibitors
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
WO2009137432A1 (en) * 2008-05-09 2009-11-12 Boehringer Ingelheim International Gmbh A method for preparing macrocycles
KR101647520B1 (ko) * 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EA022134B1 (ru) 2008-12-10 2015-11-30 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2848377A1 (en) 2011-10-28 2013-05-02 Janssen Pharmaceuticals, Inc. Improved process for preparing an intermediate of the macrocyclic protease inhibitor tmc 435
US20140100364A1 (en) 2012-10-08 2014-04-10 Abbvie Inc. Compounds Useful For Making HCV Protease Inhibitors
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
EP2914613B1 (de) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibitoren des hepatitis-c-virus
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2014152928A2 (en) 2013-03-14 2014-09-25 Achillion Pharmaceuticals, Inc. Novel processes for producing sovaprevir
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
AU2014227849A1 (en) 2013-03-15 2015-10-01 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
DE69819501T2 (de) 1997-06-27 2004-09-23 Ciba Speciality Chemicals Holding Inc. Ruthenium und osmiumcarbenkatalysatoren
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7148347B2 (en) * 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
WO2004089974A1 (en) * 2003-04-10 2004-10-21 Boehringer Ingelheim International Gmbh Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction
ES2361997T3 (es) 2003-09-22 2011-06-27 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos activos contra el virus de la hepatitis c.

Also Published As

Publication number Publication date
WO2007030656A1 (en) 2007-03-15
PL1934243T3 (pl) 2011-10-31
WO2007030656A8 (en) 2007-07-05
EP1934243A1 (de) 2008-06-25
US7951773B2 (en) 2011-05-31
CA2621360C (en) 2013-12-24
ES2364426T3 (es) 2011-09-02
US20080242835A1 (en) 2008-10-02
DK1934243T3 (da) 2011-09-05
JP2009509933A (ja) 2009-03-12
JP5190364B2 (ja) 2013-04-24
EP1934243B1 (de) 2011-05-25
CA2621360A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
ATE510846T1 (de) Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden
BRPI0508867A (pt) processo para a preparação de compostos macrocìclicos
WO2004092203A3 (en) Process for preparing macrocyclic compounds
WO2006096652A3 (en) Process for preparing macrocyclic compounds
PE20060607A1 (es) Derivados de indol tetraciclicos como agentes antivirales
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
EP1771454A4 (de) Peptidanaloga als hepatitis c-hemmer
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
DE602005013922D1 (de) Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
MY152153A (en) Macrocylic inhibitors of hepatitis c virus
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20120993A1 (es) Derivados bifenilicos como antivirales
WO2008057875A3 (en) Inhibitors of hepatitis c virus
WO2008057873A3 (en) Inhibitors of hepatitis c virus
NZ588179A (en) Antiviral therapeutic agents comprising fused tricyclic compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety
EP1598349A4 (de) Neue 2-pyridincarbonsäureamidderivate
SG164376A1 (en) Hcv ns3 protease inhibitors
NZ586232A (en) HCV protease inhibitors comprising a functionalised proline derivative
Wang et al. N-Bromosuccinimide as an oxidant for the transition-metal-free synthesis of 2-aminobenzoxazoles from benzoxazoles and secondary amines
PE20070814A1 (es) Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
WO2008046860A3 (en) Bioavailable combinations for hcv treatment
CA2722867A1 (en) A method for preparing macrocycles
DE60328915D1 (de) Verfahren zur herstellung von dem bicyclischen hexapeptide nepadutant
TH85390A (th) สารประกอบ ไตรไซคลิก-นิวคลิโอไซด์ สำหรับการรักษาภาวะติดเชื้อไวรัส

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1934243

Country of ref document: EP